ZA200808203B - Formulations for parenteral delivery of compounds and uses thereof - Google Patents

Formulations for parenteral delivery of compounds and uses thereof

Info

Publication number
ZA200808203B
ZA200808203B ZA200808203A ZA200808203A ZA200808203B ZA 200808203 B ZA200808203 B ZA 200808203B ZA 200808203 A ZA200808203 A ZA 200808203A ZA 200808203 A ZA200808203 A ZA 200808203A ZA 200808203 B ZA200808203 B ZA 200808203B
Authority
ZA
South Africa
Prior art keywords
formulations
compounds
parenteral delivery
parenteral
delivery
Prior art date
Application number
ZA200808203A
Other languages
English (en)
Inventor
Syed M Shah
Christian Ofslager
Mahdi B Fawzi
Natalyia Bazhina
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39033508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200808203(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200808203B publication Critical patent/ZA200808203B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ZA200808203A 2006-08-04 2008-09-25 Formulations for parenteral delivery of compounds and uses thereof ZA200808203B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83557406P 2006-08-04 2006-08-04

Publications (1)

Publication Number Publication Date
ZA200808203B true ZA200808203B (en) 2010-06-30

Family

ID=39033508

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808203A ZA200808203B (en) 2006-08-04 2008-09-25 Formulations for parenteral delivery of compounds and uses thereof

Country Status (25)

Country Link
US (7) US20080070975A1 (zh)
EP (1) EP2046388B1 (zh)
JP (1) JP5356231B2 (zh)
KR (1) KR20090040248A (zh)
CN (2) CN102846613A (zh)
AR (1) AR063471A1 (zh)
AU (1) AU2007281984B8 (zh)
BR (1) BRPI0708965B8 (zh)
CA (1) CA2646901C (zh)
EC (1) ECSP088752A (zh)
ES (1) ES2655863T3 (zh)
GT (1) GT200800185A (zh)
HN (1) HN2008001464A (zh)
IL (2) IL194182A (zh)
MX (1) MX2008011993A (zh)
NO (1) NO343701B1 (zh)
NZ (1) NZ597260A (zh)
PE (1) PE20080741A1 (zh)
PH (1) PH12013500801A1 (zh)
PL (1) PL2046388T3 (zh)
RU (1) RU2539387C2 (zh)
SG (1) SG174030A1 (zh)
TW (1) TWI489984B (zh)
WO (1) WO2008019115A2 (zh)
ZA (1) ZA200808203B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
WO2004091623A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200815451A (en) * 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
DK2565195T3 (en) * 2007-03-29 2015-06-29 Wyeth Llc PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
WO2009099410A1 (en) * 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r)-8-keto-methylnaltrexone
AU2008349873B2 (en) * 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
AU2013203119B2 (en) * 2008-09-30 2015-12-03 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
AU2016201221B2 (en) * 2008-09-30 2017-08-10 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
MX344786B (es) * 2009-07-28 2017-01-06 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
SG183133A1 (en) 2010-03-11 2012-09-27 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
RS59526B1 (sr) 2010-10-21 2019-12-31 Rtu Pharmaceuticals Llc Formulacije ketorolaka spremne za upotrebu
CN102525911B (zh) * 2012-03-20 2013-09-18 南京臣功制药股份有限公司 一种溴甲纳曲酮注射液及其制备方法
CN103239452A (zh) * 2013-01-25 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种溴甲基纳曲酮药物组合物
AU2014230834B9 (en) 2013-03-14 2017-08-31 Fresenius Kabi Deutschland Gmbh Injectable morphine formulations
WO2014140097A1 (en) 2013-03-14 2014-09-18 Becton Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
EP3718404A1 (en) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progession
CN105769755A (zh) * 2014-12-23 2016-07-20 北大方正集团有限公司 一种溴甲纳曲酮注射液及其制备方法
US10695402B2 (en) * 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
AU2018321157B2 (en) 2017-08-24 2024-03-28 Novo Nordisk A/S GLP-1 compositions and uses thereof
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
CN110960486B (zh) * 2018-09-29 2022-05-13 北京凯因科技股份有限公司 一种溴甲纳曲酮注射液组合物
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CN111303093A (zh) * 2020-02-21 2020-06-19 重庆医药高等专科学校 一种溴甲纳曲酮杂质的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221707D0 (en) * 1992-10-15 1992-12-02 Smithkline Beecham Plc Pharmaceutical composition
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
CA2385990A1 (en) * 1999-09-29 2001-04-05 The Procter & Gamble Company Compositions having improved stability
MXPA04008772A (es) * 2002-03-14 2004-12-06 Euro Celtique Sa Composiciones de clorhidrato de naltrexona.
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
WO2004091623A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS

Also Published As

Publication number Publication date
BRPI0708965A2 (pt) 2011-06-28
IL221795A0 (en) 2012-10-31
BRPI0708965B8 (pt) 2021-05-25
HN2008001464A (es) 2011-03-30
US20230414490A1 (en) 2023-12-28
ECSP088752A (es) 2008-10-31
US20150025100A1 (en) 2015-01-22
US20100249169A1 (en) 2010-09-30
CA2646901C (en) 2015-12-22
US20200179270A1 (en) 2020-06-11
AR063471A1 (es) 2009-01-28
PE20080741A1 (es) 2008-08-06
JP5356231B2 (ja) 2013-12-04
EP2046388B1 (en) 2017-12-13
TW200815007A (en) 2008-04-01
IL194182A (en) 2013-08-29
CN101405031A (zh) 2009-04-08
AU2007281984B2 (en) 2013-12-05
IL221795B (en) 2018-06-28
PH12013500801B1 (en) 2014-10-20
JP2009545603A (ja) 2009-12-24
RU2008138266A (ru) 2010-03-27
AU2007281984A1 (en) 2008-02-14
WO2008019115A3 (en) 2008-07-03
MX2008011993A (es) 2008-10-01
PL2046388T3 (pl) 2018-04-30
US20160338946A1 (en) 2016-11-24
SG174030A1 (en) 2011-09-29
CN101405031B (zh) 2012-10-10
NZ597260A (en) 2013-07-26
NO20083973L (no) 2009-01-06
KR20090040248A (ko) 2009-04-23
US20220023200A1 (en) 2022-01-27
WO2008019115A2 (en) 2008-02-14
GT200800185A (es) 2009-08-27
PH12013500801A1 (en) 2014-10-20
AU2007281984B8 (en) 2014-01-09
RU2539387C2 (ru) 2015-01-20
ES2655863T3 (es) 2018-02-22
CA2646901A1 (en) 2008-02-14
CN102846613A (zh) 2013-01-02
BRPI0708965B1 (pt) 2020-01-07
EP2046388A2 (en) 2009-04-15
US20080070975A1 (en) 2008-03-20
TWI489984B (zh) 2015-07-01
NO343701B1 (no) 2019-05-13

Similar Documents

Publication Publication Date Title
IL221795A0 (en) Formulations for parenteral delivery of compounds and uses thereof
EP2101745A4 (en) DISTRIBUTION OF MEDICINAL PRODUCTS
EP2032156A4 (en) COMPOSITIONS AND METHOD FOR THE DELIVERY OF OXYGEN
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
ZA200808530B (en) Pharmaceutical composition for external use
ZA200808531B (en) Pharmaceutical composition for external use
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
HK1138732A1 (zh) 藥學成份
EP2010162A4 (en) COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
EP2066174A4 (en) COMPOSITIONS WITH ALPHA-1-ANTITRYPINE AND METHOD OF USE THEREOF
ZA200807408B (en) Compositions and methods for delivery of amino-functional drugs
EP2185112A4 (en) STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS
IL197235A0 (en) Therapeutic compositions
ZA200810178B (en) Pharmaceutical compositions for sustained release of phenyephrine
EP2070919A4 (en) SPIROCHINONE COMPOUND AND PHARMACEUTICAL COMPOSITION
EP2124908A4 (en) CONNECTIONS AND ITS USE
EP2114374A4 (en) PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
EP2120563A4 (en) CONNECTIONS AND ITS USES
IL198160A0 (en) Pharmaceutical formulations
EP2114404A4 (en) COMPOUND AND PHARMACEUTICAL COMPOSITION
EP2099459A4 (en) COMPOUNDS AND USES THEREOF
EP1993591A4 (en) TARGETED RELEASE OF PHARMACEUTICAL COMPOUNDS